Mona Shahriari, MD, Assistant Clinical Professor of Dermatology at Yale University School of Medicine, and Dermatology Times® editorial advisory board member explains her role in Maui Derm Hawaii 2023, and what the Maui Derm Hawaii conference means to her, and the field of dermatology.
Mona Shahriari, MD: Hi, my name is Mona Shahriari. I'm assistant clinical professor of Dermatology at Yale University and the associate director of clinical trials at Central Connecticut Dermatology research. I'm also an editorial advisory board member for Dermatology Times®. Today I'm coming to you from beautiful Maui at the Maui Derm Hawaii conference is actually my fifth time attending this conference. And I absolutely love to come here; the spectrum of different aspects of dermatology that you get to learn about whether it's medical, pediatrics, or cosmetic surgical; there's always something that I learn a little something extra about. So today, I'm very excited to be talking on behalf of one of the latest additions to the topic dermatitis therapy toolbox, RINVOQ, so that is what I'm going to be speaking on at this conference. But being in Maui, you can't really beat that, and getting a chance to gain CME as well as network with some of the leaders in dermatology; one of the main reasons I've come out to this conference year after year.
[What she hopes the audience takes away from her talk]
I hope that they understand that we have a busy toolbox currently of medications to treat atopic dermatitis, and this innovation in the field will help them better treat their patients and also help them understand that atopic dermatitis goes beyond the skin. There's a multi-dimensional burden of AD that you can't see. So to keep that in mind when they're assessing their patients with atopic dermatitis.
Transcript edited for clarity